Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops therapeutics to treat chronic and life-threatening diseases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Arrowhead Pharmaceuticals' stock with a target price of $48.31, indicating good growth potential.
Financial Health
Arrowhead Pharmaceuticals is showing solid revenue and cash flow, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ARWR
Pioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage pipeline
Progress in human trials can materially change valuation, so clinical read-outs are worth watching — though outcomes are binary and can be unpredictable.
RNAi platform focus
A platform approach can create multiple opportunities if delivery and safety perform well, but technical and regulatory hurdles remain.
Partnerships and deals
Collaborations with larger pharma can de‑risk development and provide milestones, yet deal terms and reliance on partners also shape future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
